Evropska unija - slovenščina - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - zavrnitev presadka - imunosupresivi - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Evropska unija - slovenščina - EMA (European Medicines Agency)

gsk vaccines s.r.l. - zunanjo membrano semenskih mešičkov iz neisseria meningitidis skupina b (sev nz 98/254), rekombinantne neisseria meningitidis skupina b fhbp fuzijski protein, rekombinantne neisseria meningitidis skupina b nada beljakovin, rekombinantne neisseria meningitidis skupina b nhba fuzijski protein - meningitis, meningokokni - meningococcal cepiva - aktivna imunizacija proti invazivni bolezni, ki jo povzročajo sevi neisseria meningitidis serogroup-b.

Evropska unija - slovenščina - EMA (European Medicines Agency)

pfizer europe ma eeig - neisseria meningitidis serogroup b fhbp (rekombinantni lipidirani fhbp (faktor h vezavni protein)) poddružina a; neisseria meningitidis serogroup b fhbp (rekombinantni lipidirani fhbp (faktor h vezavnega proteina)) podfamil b - meningitis, meningokokni - bacterial vaccines, meningococcal vaccines - trumenba je indicirana za aktivno imunizacijo posameznikov, starih 10 let in več, da preprečijo invazivno meningokokno bolezen, ki jo povzroča serotipa b neisseria meningitidis. uporaba tega cepiva mora biti v skladu z uradnimi priporočili.

Evropska unija - slovenščina - EMA (European Medicines Agency)

pfizer europe ma eeig - neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid - meningitis, meningokokni - cepiva - nimenrix je indicirano za aktivne imunizacije posameznikov v starosti od 6 tednov proti invazivni meningokokni bolezni, ki povzroča neisseria meningitidis skupine a, c, w-135, in y.

Evropska unija - slovenščina - EMA (European Medicines Agency)

sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningitis, meningokokni - cepiva - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. the use of this vaccine should be in accordance with available official recommendations.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pfizer luxembourg sarl - virus klopnega meningoencefalitisa, inaktivirani - suspenzija za injiciranje - virus klopnega meningoencefalitisa, inaktivirani 2,4 µg / 0,5 ml - cepivo proti klopnemu meningoencefalitisu z inaktiviranimi virusi

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pfizer luxembourg sarl - virus klopnega meningoencefalitisa, inaktivirani - suspenzija za injiciranje - virus klopnega meningoencefalitisa, inaktivirani 2,4 µg / 0,5 ml - cepivo proti klopnemu meningoencefalitisu z inaktiviranimi virusi

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gsk vaccines gmbh - virus klopnega meningoencefalitisa, inaktivirani - suspenzija za injiciranje - virus klopnega meningoencefalitisa, inaktivirani 0,75 µg / 0,25 ml - cepivo proti klopnemu meningoencefalitisu, s celimi virusi, inaktivirano

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gsk vaccines gmbh - virus klopnega meningoencefalitisa, inaktivirani - suspenzija za injiciranje - virus klopnega meningoencefalitisa, inaktivirani 0,75 µg / 0,25 ml - cepivo proti klopnemu meningoencefalitisu, s celimi virusi, inaktivirano

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gsk vaccines gmbh - virus klopnega meningoencefalitisa, inaktivirani - suspenzija za injiciranje - virus klopnega meningoencefalitisa, inaktivirani 0,75 µg / 0,25 ml - cepivo proti klopnemu meningoencefalitisu z inaktiviranimi virusi